Horizon Pharma (HZNP) – Investment Analysts’ Recent Ratings Updates

Horizon Pharma (NASDAQ: HZNP) has recently received a number of price target changes and ratings updates:

  • 4/19/2019 – Horizon Pharma was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/4/2019 – Horizon Pharma had its price target raised by analysts at BMO Capital Markets to $29.00. They now have a “market perform” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 4/4/2019 – Horizon Pharma was given a new $33.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 4/2/2019 – Horizon Pharma had its price target raised by analysts at Cantor Fitzgerald from $26.00 to $32.00. They now have a “buy” rating on the stock. They wrote, “. We have updated our financial model to include: 1) HZNP’s recent equity offering, and 2) sales for teprotumumab starting in 2020, given the positive Phase 3 results earlier this year. Both the equity raise and positive Phase 3 data support our OW rating on HZNP shares. Therefore, we are raising our PT to $32 from $26. The increase in our PT is driven by upward earnings revisions for 2020+ given we now include risk adjusted sales for teprotumumab in our financial model.””
  • 3/8/2019 – Horizon Pharma was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $32.00 price target on the stock.
  • 3/1/2019 – Horizon Pharma had its price target raised by analysts at JMP Securities from $26.00 to $38.00. They now have an “outperform” rating on the stock.
  • 3/1/2019 – Horizon Pharma had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $27.00 price target on the stock.
  • 3/1/2019 – Horizon Pharma had its price target raised by analysts at Jefferies Financial Group Inc to $34.00. They now have a “buy” rating on the stock.
  • 2/28/2019 – Horizon Pharma was given a new $33.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 2/26/2019 – Horizon Pharma was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/20/2019 – Horizon Pharma was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

Shares of HZNP stock traded up $0.32 on Friday, reaching $24.92. 1,198,139 shares of the stock were exchanged, compared to its average volume of 1,895,853. The company has a market cap of $4.60 billion, a P/E ratio of 13.62, a PEG ratio of 1.48 and a beta of 1.14. Horizon Pharma PLC has a one year low of $12.55 and a one year high of $29.44. The company has a quick ratio of 1.97, a current ratio of 2.03 and a debt-to-equity ratio of 1.80.

Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.13. The company had revenue of $355.50 million during the quarter, compared to the consensus estimate of $334.22 million. Horizon Pharma had a positive return on equity of 34.09% and a negative net margin of 6.34%. The firm’s quarterly revenue was up 29.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 earnings per share. As a group, equities research analysts anticipate that Horizon Pharma PLC will post 1.7 earnings per share for the current fiscal year.

In related news, EVP Geoffrey M. Curtis sold 8,835 shares of the company’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $23.15, for a total value of $204,530.25. Following the completion of the sale, the executive vice president now owns 32,202 shares in the company, valued at $745,476.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Geoffrey M. Curtis sold 10,080 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $21.21, for a total value of $213,796.80. Following the completion of the sale, the executive vice president now owns 35,367 shares of the company’s stock, valued at approximately $750,134.07. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Private Capital Group LLC increased its holdings in Horizon Pharma by 141.5% in the fourth quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,150 shares during the last quarter. Rehmann Capital Advisory Group increased its holdings in Horizon Pharma by 2,162.2% in the third quarter. Rehmann Capital Advisory Group now owns 7,420 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 7,092 shares during the last quarter. Nkcfo LLC bought a new stake in Horizon Pharma in the first quarter valued at about $246,000. SG Americas Securities LLC increased its holdings in Horizon Pharma by 79.5% in the fourth quarter. SG Americas Securities LLC now owns 9,438 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 4,179 shares during the last quarter. Finally, Meeder Asset Management Inc. increased its holdings in Horizon Pharma by 631.9% in the fourth quarter. Meeder Asset Management Inc. now owns 9,947 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 8,588 shares during the last quarter. Institutional investors and hedge funds own 82.02% of the company’s stock.

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

See Also: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.